Tetranor PGDM analyses for the amyotrophic lateral sclerosis: Positive and simple diagnosis and evaluation of drug effect

Amyotrophic lateral sclerosis (ALS) is a late-onset, progressive motor neuronal degenerative disease occurring as sporadically and as a familial disorder. The patients with ALS typically become progressively paralyzed and develop respiratory failure that eventually leads to death within 3–5 years. For this disease, there is no effective diagnostic method and also drug. This report describes a simple and useful diagnostic biomarker for ALS. Our findings suggest that the combination analysis of a metabolite of prostaglandin D2, 11,15-dioxo-9-hydroxy-,2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor PGDM and tPGDM) with creatinine is the diagnostic approach for ALS with high accuracy. tPGDM has the potential to be an important diagnostic tool in the pre-symptomatic stages and progression evaluation of ALS, and also to be a biomarker for the evaluation of drug effect.

► tPGDM is a novel diagnostic approach of ALS through the combination of tPGDM and creatinine analyses.
► There is a correlation between the increase of urinary tPGDM concentration and the ALS progression.
► tPGDM has potential to be a biomarker for the evaluation of drug effect.